Skip to main content
SpringerLink
Log in

Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Acyclovir is a Biopharmaceutics Classification System (BCS) class III antiviral agent which is only absorbed in the upper part of the gastrointestinal tract. This study aimed to establish a new in vitro-in vivo correlation (IVIVC) platform based on population pharmacokinetic modeling for drugs with site-dependent absorption using acyclovir as a model drug. Three types of sustained-release (SR; 500 mg) acyclovir tablets were prepared by the wet granulation method. The in vitro dissolution profiles of the acyclovir SR tablets and the immediate-release (IR; 200 mg) were determined by the paddle method and their in vivo pharmacokinetics were evaluated in Beagle dogs. A population pharmacokinetic model was developed using S-ADAPT. By separating the dissolution and absorption processes, the population pharmacokinetic model adequately described all the in vivo pharmacokinetic data and estimated the in vivo dissolution profiles. The changes of absorption rate over time after oral administration were also successfully estimated. The parameter estimates of the in vitro and in vivo drug releases were correlated by linear regression. Finally, the in vivo pharmacokinetic profiles were well predicted by the developed IVIVC model from the in vitro dissolution data with the prediction errors within 8.26% and 10.06% for the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC), respectively. The present approach provides a better understanding of the in vivo absorption for drugs that have limited absorption window and may be useful for their new formulation design and development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Gnann JW Jr, Barton NH, Whitley RJ. Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy. 1983;3(5):275–83.

    Article  CAS  Google Scholar 

  2. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29–37.

    Article  Google Scholar 

  3. Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother. 2000;44(1):207–9.

    Article  CAS  Google Scholar 

  4. Bras AP, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol. 2001;8(4):207–11.

    CAS  PubMed  Google Scholar 

  5. Lewis LD, Fowle AS, Bittiner SB, Bye A, Isaacs PE. Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br J Clin Pharmacol. 1986;21(4):459–62.

    Article  CAS  Google Scholar 

  6. Groning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm. 1998;46(3):285–91.

    Article  CAS  Google Scholar 

  7. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249–57.

    Article  CAS  Google Scholar 

  8. Kim TH, Paik SH, Chi YH, Bulitta JB, Lee DY, Lim JY, et al. Regional absorption of fimasartan in the gastrointestinal tract by an improved in situ absorption method in rats. Pharmaceutics. 2018;10(4):174.

  9. U.S. FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997.

    Google Scholar 

  10. Kim TH, Shin S, Shin BS. Model-based drug development: application of modeling and simulation in drug development. J Pharm Investig. 2018;48(4):431-41.

  11. Kim TH, Bulitta JB, Kim D-H, Shin S, Shin BS. Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. Int J Pharm. 2019;556:276–86.

    Article  CAS  Google Scholar 

  12. Wagner JG, Nelson E. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963;52(6):610–1.

    Article  CAS  Google Scholar 

  13. Loo J, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968;57(6):918–28.

    Article  CAS  Google Scholar 

  14. Kim TH, Shin S, Bulitta JB, Youn YS, Yoo SD, Shin BS. Development of a physiologically relevant population pharmacokinetic in vitro-in vivo correlation approach for designing extended-release oral dosage formulation. Mol Pharm. 2017;14(1):53–65.

    Article  Google Scholar 

  15. Brown SD, Bartlett MG, White CA. Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats. Antimicrob Agents Chemother. 2003;47:991–6. https://doi.org/10.1128/aac.47.3.991-996.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Abuhelwa AY, Mudge S, Hayes D, Upton RN, Foster DJ. Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH, and pharmacokinetics: itraconazole as a model drug. Pharm Res. 2016;33(7):1782–94.

    Article  CAS  Google Scholar 

  17. U.S. FDA. Guidance for Industry: Bioanalytical Method Validation. 2018.

    Google Scholar 

  18. Seta Y, Higuchi F, Kawahara Y, Nishimura K, Okada R. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int J Pharm. 1988;41(3):245–54.

    Article  CAS  Google Scholar 

  19. Grass GM, Morehead WT. Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989;6(9):759–65.

    Article  CAS  Google Scholar 

  20. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci. 1986;75(3):271–4.

    Article  CAS  Google Scholar 

  21. Youngberg CA, Wlodyga J, Schmaltz S, Dressman JB. Radiotelemetric determination of gastrointestinal pH in four healthy beagles. Am J Vet Res. 1985;46(7):1516–21.

    CAS  PubMed  Google Scholar 

  22. Sagawa K, Li F, Liese R, Sutton SC. Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. J Pharm Sci. 2009;98(7):2494–500.

    Article  CAS  Google Scholar 

  23. Mahar KM, Portelli S, Coatney R, Chen EP. Gastric pH and gastric residence time in fasted and fed conscious beagle dogs using the Bravo pH system. J Pharm Sci. 2012;101(7):2439–48.

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported by the National Research Foundation of Korea (NRF) [grant numbers 2017R1D1A1A02018615 and 2018R1A2B6004928] and by Ministry of Food and Drug Safety in 2019 [grant number 16173MFDS542].

Author information

Author notes

  1. Soyoung Shin and Tae Hwan Kim contributed equally to this work.

Authors and Affiliations

  1. College of Pharmacy, Wonkwang University, Iksan, Jeonbuk, 54538, Korea

    Soyoung Shin

  2. College of Pharmacy, Daegu Catholic University, Gyeongsan, Gyeongbuk, 38430, Korea

    Tae Hwan Kim

  3. School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Korea

    Da Young Lee, Seung Eun Chung & Beom Soo Shin

  4. Department of Pharmaceutics, Ernest Mario School of Pharmacy, The State University of New Jersey, Piscataway, New Jersey, 08854, USA

    Jong Bong Lee

  5. KNOTUS Co., Ltd. Research center, Guri, Gyeonggi, 11910, Korea

    Do-Hyung Kim

Authors
  1. Soyoung Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tae Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Da Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seung Eun Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jong Bong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Do-Hyung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Beom Soo Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beom Soo Shin.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, S., Kim, T.H., Lee, D.Y. et al. Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study. AAPS J 22, 27 (2020). https://doi.org/10.1208/s12248-019-0382-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-019-0382-2

KEY WORDS

Search

Navigation